Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)

Peer Review reports

Original Submission
21 Dec 2017	Submitted	Original manuscript
22 Jul 2018	Reviewed	Reviewer Report - Marc Steben
3 Aug 2018	Reviewed	Reviewer Report - Willem Meijden
10 Sep 2018	Author responded	Author comments - Macey Murray
Resubmission - Version 2
10 Sep 2018	Submitted	Manuscript version 2
14 Sep 2018	Reviewed	Reviewer Report - Willem Meijden
18 Sep 2018	Reviewed	Reviewer Report - Marc Steben
15 Oct 2018	Author responded	Author comments - Macey Murray
Resubmission - Version 3
15 Oct 2018	Submitted	Manuscript version 3
Publishing
18 Oct 2018	Editorially accepted
6 Nov 2018	Article published	10.1186/s12874-018-0581-z

Back to article page